Sphingosine-1-Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third-Generation EGFR Inhibitor

Abstract

The third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has significantly improved the survival in EGFR-mutant lung cancer patients. Our team developed limertinib (ASK120067), a novel third-generation EGFR inhibitor with remarkable antitumor effects, which has been launched in China. Despite initial therapeutic responses, EGFR TKIs-treated patients ultimately experience fatal metastatic recurrence and disease progression. However, the underlying mechanism of driving metastasis remains poorly understood. Here, we aim to investigate the pro-metastatic mechanism following treatment with third-generation EGFR TKIs. Transcriptomics analyses of EGFR TKI-resistant tumor models revealed an aberrant upregulation of S1PR3, which conferred enhanced metastatic potential to lung cancer. S1PR3 inhibition dramatically reduced metastasis in resistant cells, while its overexpression potentiated metastatic abilities in parental cells. Notably, S1PR3 was highly enriched in clinical samples with AZD9291 resistance and correlates with poor prognosis. Mechanistically, we found that S1PR3 upregulated RAC1-GTP expression to activate PAK1, thereby promoting epithelial-mesenchymal transition (EMT) and enhancing metastatic capacity of resistant cells. Further studies identified that the overexpression of fibroblast growth factor receptor 1 (FGFR1) increased S1PR3 expression through signal transducer and activator of transcription 4 (STAT4) to promote the emergence of metastatic-resistant cells. Importantly, targeting S1PR3 or FGFR1 blocks metastasis in EGFR TKI-resistant models.

Keywords

EGFR inhibitor / EMT / lung cancer / metastasis / S1PR3

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249.

[2] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer Statistics, 2022,” CA: A Cancer Journal for Clinicians 72, no. 1 (2022): 7–33.

[3] X. Guan, “Cancer Metastases: Challenges and Opportunities,” Acta Pharmaceutica Sinica B 5, no. 5 (2015): 402–418.

[4] D. E. Dawe, J. N. Greenspoon, and P. M. Ellis, “Brain Metastases in Non-small-cell Lung Cancer,” Clinical Lung Cancer 15, no. 4 (2014): 249–257.

[5] W. Ma, B. Zhao, Y. Lang, et al., “The 5-Year Survival Outcomes Analysis of EGFR-TKI or/and Chemotherapy as Initial Adjuvant Therapy for Completely Resected IIIA Non-small Cell Lung Cancer,” Lung Cancer 210 (2025): 108721.

[6] D. A. Cross, S. E. Ashton, S. Ghiorghiu, et al., “AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer,” Cancer Discovery 4, no. 9 (2014): 1046–1061.

[7] S. L. Greig, “Osimertinib: First Global Approval,” Drugs 76, no. 2 (2016): 263–273.

[8] T. Zhang, R. Qu, S. Chan, et al., “Discovery of a Novel Third-Generation EGFR Inhibitor and Identification of a Potential Combination Strategy to Overcome Resistance,” Molecular Cancer 19, no. 1 (2020): 90.

[9] V. Gregorc, C. Lazzari, N. Karachaliou, R. Rosell, and M. Santarpia, “Osimertinib in Untreated Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced Non-Small Cell Lung Cancer,” Translational Lung Cancer Research 7, no. supplement, S2 (2018): S165–S170.

[10] C. Ricordel, L. Friboulet, F. Facchinetti, and J. C. Soria, “Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790M-Mutant Lung Cancer,” Annals of Oncology 29, supplement, S1 (2018): i28–i37.

[11] Y. Wang, J. Zhang, S. Ren, et al., “Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors,” Cell Reports 28, no. 2 (2019): 512–525.e516.

[12] W. Xu, H. Yang, K. Xu, et al., “Transitional CXCL14(+) Cancer-Associated Fibroblasts Enhance Tumour Metastasis and Confer Resistance to EGFR-TKIs, Revealing Therapeutic Vulnerability to Filgotinib in Lung Adenocarcinoma,” Clinical and Translational Medicine 15, no. 4 (2025): e70281.

[13] F. Weiss, D. Lauffenburger, and P. Friedl, “Towards Targeting of Shared Mechanisms of Cancer Metastasis and Therapy Resistance,” Nature Reviews Cancer 22, no. 3 (2022): 157–173.

[14] Y. Yang, Y. Wang, and X. Che, “Integrin α5 Promotes Migration and Invasion Through the FAK/STAT3/AKT Signaling Pathway in Icotinib-Resistant Non-Small Cell Lung Cancer Cells,” Oncology Letters 22, no. 1 (2021): 556.

[15] A. K. Biswas, S. Han, Y. Tai, et al., “Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer,” Cancer Discovery 12, no. 4 (2022): 1002–1021.

[16] M. Y. Luo, Y. Zhou, W. M. Gu, et al., “Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma,” Cancer Research 82, no. 19 (2022): 3516–3531.

[17] A. K. Buck, S. E. Serfling, T. Lindner, et al., “CXCR4-Targeted Theranostics in Oncology,” European Journal of Nuclear Medicine and Molecular Imaging 49, no. 12 (2022): 4133–4144.

[18] S. Park, L. Wu, J. Tu, et al., “Unlike LGR4, LGR5 Potentiates Wnt-β-Catenin Signaling Without Sequestering E3 Ligases,” Science Signaling 13, no. 660 (2020): eaaz4051.

[19] K. S. Carmon, X. Gong, J. Yi, et al., “LGR5 Receptor Promotes Cell-Cell Adhesion in Stem Cells and Colon Cancer Cells via the IQGAP1-Rac1 Pathway,” Journal of Biological Chemistry 292, no. 36 (2017): 14989–15001.

[20] D. F. Legler, E. Uetz-von Allmen, and M. A. Hauser, “CCR7: Roles in Cancer Cell Dissemination, Migration and Metastasis Formation,” International Journal of Biochemistry & Cell Biology 54 (2014): 78–82.

[21] J. Wu, L. Li, J. Liu, et al., “CC Chemokine Receptor 7 Promotes Triple-Negative Breast Cancer Growth and Metastasis,” Acta Biochimica et Biophysica Sinica 50, no. 9 (2018): 835–842.

[22] Q. Li, Y. Li, C. Lei, Y. Tan, and G. Yi, “Sphingosine-1-Phosphate Receptor 3 Signaling,” Clinica Chimica Acta 519 (2021): 32–39.

[23] R. Bar-Shavit, M. Maoz, A. Kancharla, et al., “G Protein-Coupled Receptors in Cancer,” International Journal of Molecular Sciences 17, no. 8 (2016): 1320.

[24] P. K. Chaudhary and S. Kim, “An Insight Into GPCR and G-Proteins as Cancer Drivers,” Cells 10, no. 12 (2021): 3288.

[25] V. Brinkmann, “Sphingosine 1-Phosphate Receptors in Health and Disease: Mechanistic Insights From Gene Deletion Studies and Reverse Pharmacology,” Pharmacology & Therapeutics 115, no. 1 (2007): 84–105.

[26] A. Hsu, W. Zhang, J. F. Lee, et al., “Sphingosine-1-Phosphate Receptor-3 Signaling Up-Regulates Epidermal Growth Factor Receptor and Enhances Epidermal Growth Factor Receptor-mediated Carcinogenic Activities in Cultured Lung Adenocarcinoma Cells,” International Journal of Oncology 40, no. 5 (2012): 1619–1626.

[27] J. Zhao, J. Liu, J. F. Lee, et al., “TGF-β/SMAD3 Pathway Stimulates Sphingosine-1 Phosphate Receptor 3 Expression: Implication of Sphingosine-1 Phosphate Receptor 3 in Lung Adenocarcinoma Progression,” Journal of Biological Chemistry 291, no. 53 (2016): 27343–27353.

[28] E. S. Kim, J. S. Kim, S. G. Kim, S. Hwang, C. H. Lee, and A. Moon, “Sphingosine 1-Phosphate Regulates Matrix Metalloproteinase-9 Expression and Breast Cell Invasion Through S1P3-Gαq Coupling,” Journal of Cell Science 124, no. Pt 13 (2011): 2220–2230.

[29] D. Enrico, F. Tsou, G. Catani, et al., “Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report,” JTO Clinical and Research Reports 4, no. 2 (2023): 100456.

[30] R. Minari, P. Bordi, and M. Tiseo, “Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in T790M-Positive Non-Small Cell Lung Cancer: Review on Emerged Mechanisms of Resistance,” Translational Lung Cancer Research 5, no. 6 (2016): 695–708.

[31] J. P. Thiery, H. Acloque, R. Y. Huang, and M. A. Nieto, “Epithelial-Mesenchymal Transitions in Development and Disease,” Cell 139, no. 5 (2009): 871–890.

[32] D. Jia, M. K. Jolly, P. Kulkarni, and H. Levine, “Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights From Dynamical Systems Theory,” Cancers 9, no. 7 (2017): 70.

[33] Z. H. Tang and J. J. Lu, “Osimertinib Resistance in Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies,” Cancer Letters 420 (2018): 242–246.

[34] M. M. Chang, S. Z. Wu, S. H. Yang, C. C. Wu, C. Y. Wang, and B. M. Huang, “FGF9/FGFR1 Promotes Cell Proliferation, Epithelial-Mesenchymal Transition, M2 Macrophage Infiltration and Liver Metastasis of Lung Cancer,” Translational Oncology 14, no. 11 (2021): 101208.

[35] H. Iioka, K. Saito, M. Sakaguchi, T. Tachibana, K. Homma, and E. Kondo, “Crumbs3 is a Critical Factor That Regulates Invasion and Metastasis of Colon Adenocarcinoma via the Specific Interaction With FGFR1,” International Journal of Cancer 145, no. 10 (2019): 2740–2753.

[36] K. Wang, W. Ji, and Y. Yu, “FGFR1-ERK1/2-SOX2 Axis Promotes Cell Proliferation, Epithelial-Mesenchymal Transition, and Metastasis in FGFR1-Amplified Lung Cancer,” Oncogene 37, no. 39 (2018): 5340–5354.

[37] W. J. Xue, M. T. Li, L. Chen, L. P. Sun, and Y. Y. Li, “Recent Developments and Advances of FGFR as a Potential Target in Cancer,” Future Medicinal Chemistry 10, no. 17 (2018): 2109–2126.

[38] Y. Zhang and L. Niswander, “Zic2 is Required for Enteric Nervous System Development and Neurite Outgrowth: A Mouse Model of Enteric Hyperplasia and Dysplasia,” Neurogastroenterology and Motility 25, no. 6 (2013): 538–541.

[39] S. Peters, T. Mok, A. Passaro, and P. A. Jänne, “The Promising Evolution of Targeted Therapeutic Strategies in Cancer,” Cancer Discovery 11, no. 4 (2021): 810–814.

[40] Y. Liang, H. F. Pan, and D. Q. Ye, “Therapeutic Potential of STAT4 in Autoimmunity,” Expert Opinion on Therapeutic Targets 18, no. 8 (2014): 945–960.

[41] X. Xiao, M. Lai, Z. Song, et al., “Design, Synthesis and Pharmacological Evaluation of Bicyclic and Tetracyclic Pyridopyrimidinone Analogues as New KRAS(G12C) Inhibitors,” European Journal of Medicinal Chemistry 213 (2021): 113082.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.